A Phase 1 interventional study of NVP-1402 in Healthy, sponsored by NVP Healthcare. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-17.
Sponsored by NVP Healthcare · Phase 1, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the food effect on the pharmacokinetics of NVP-1402 in healthy male volunteers.
This study is designed as randomized, open-label, single oral dose, two-treatment, two sequence crossover active-controlled and crossover assignment for evaluate the food effect on the pharmacokinetics of NVP-1402 in healthy male subjects.
NVP Healthcare is the lead sponsor of 22 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NVP-1402 was administered once a day for 24 hours
Drug: NVP-1402
NVP-1402 was administered once a day for 24 hours
Drug: NVP-1402
Oral
Pharmacokinetics of plasma: Cmax
Maximum measured concentration of the analyte in plasma
Time frame: up to 24 hours after administration
Pharmacokinetics of plasma: AUClast
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point
Time frame: up to 24 hours after administration
Pharmacokinetics of plasma: AUCinf
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity
Time frame: up to 24 hours after administration
Pharmacokinetics of plasma: Tmax
Time from dosing to the maximum measured concentration of the analyte in plasma
Time frame: up to 24 hours after administration
Pharmacokinetics of plasma: t1/2
Terminal half-life of the analyte in plasma
Time frame: up to 24 hours after administration
Ran from Dec 2017 to primary completion in Jan 2018, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.